Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beyond Air Inc (XAIR)

Beyond Air Inc (XAIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,375
  • Shares Outstanding, K 8,009
  • Annual Sales, $ 3,710 K
  • Annual Income, $ -46,630 K
  • EBIT $ -33 M
  • EBITDA $ -29 M
  • 60-Month Beta 0.31
  • Price/Sales 1.97
  • Price/Cash Flow N/A
  • Price/Book 0.55
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -7.58
  • Most Recent Earnings $-1.25 on 11/10/25
  • Next Earnings Date 02/09/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 95.97%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Expected Move (DTE 24) 0.0340 (3.18%)
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A
  • Expected Range 1.0360 to 1.1040

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -3.00
  • Growth Rate Est. (year over year) +33,400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8500 +0.87%
on 12/23/25
1.3800 -37.87%
on 11/26/25
-0.4526 (-34.55%)
since 11/21/25
3-Month
0.8500 +0.87%
on 12/23/25
2.7800 -69.16%
on 10/09/25
-1.4526 (-62.88%)
since 09/23/25
52-Week
0.8500 +0.87%
on 12/23/25
11.2000 -92.34%
on 12/27/24
-7.9686 (-90.29%)
since 12/23/24

Most Recent Stories

More News
Beyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil

GARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

XAIR : 0.8574 (-6.89%)
Beyond Air® Announces Transition of Chief Financial Officer

GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

XAIR : 0.8574 (-6.89%)
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma...

XAIR : 0.8574 (-6.89%)
Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

XAIR : 0.8574 (-6.89%)
Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

GARDEN CITY, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused...

XAIR : 0.8574 (-6.89%)
Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds

GARDEN CITY, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused...

XAIR : 0.8574 (-6.89%)
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults

BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ:...

XAIR : 0.8574 (-6.89%)
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

GARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused...

XAIR : 0.8574 (-6.89%)
Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan

GARDEN CITY, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on...

XAIR : 0.8574 (-6.89%)
Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Increased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024 Awarded a national group purchasing agreement for therapeutic gases by Premier,...

XAIR : 0.8574 (-6.89%)

Business Summary

Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company. It is engaged in developing a Nitric Oxide Generator and Delivery System. The company's principal product is AirNOvent which is in clinical stage. Beyond Air Inc., formerly known as AIT Therapeutics Inc., is based in Garden...

See More

Key Turning Points

3rd Resistance Point 0.9716
2nd Resistance Point 0.9458
1st Resistance Point 0.9016
Last Price 0.8574
1st Support Level 0.8316
2nd Support Level 0.8058
3rd Support Level 0.7616

See More

52-Week High 11.2000
Fibonacci 61.8% 7.2463
Fibonacci 50% 6.0250
Fibonacci 38.2% 4.8037
Last Price 0.8574
52-Week Low 0.8500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar